EMERGENT BIOSOLUTIONS INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- EMERGENT BIOSOLUTIONS INC. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $7.70M.
- EMERGENT BIOSOLUTIONS INC. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $8.20M.
- EMERGENT BIOSOLUTIONS INC. stock issued during period, value, new issues for fiscal 2024 was $7.70M, a 8.33% decline from fiscal 2023.
- EMERGENT BIOSOLUTIONS INC. stock issued during period, value, new issues for fiscal 2023 was $8.40M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2024-12-31 | $7.70M 10-K · filed 2026-02-27 | |
| 2024-09-30 | $7.70M 10-Q · filed 2025-10-30 | |
| 2023-12-31 | $8.40M 10-K · filed 2026-02-27 | |
| 2023-06-30 | $8.20M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |